Found: 3
Select item for more details and to access through your institution.
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA.
- Published in:
- PharmacoEconomics, 2024, v. 42, n. 5, p. 569, doi. 10.1007/s40273-024-01358-y
- By:
- Publication type:
- Article
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 9, p. 941, doi. 10.1007/s40273-020-00919-1
- By:
- Publication type:
- Article
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
- Published in:
- 2016
- By:
- Publication type:
- journal article